Opioid Medications

  • Stephen Kishner
  • Juliet P. Tran


Opioids are a group of compounds that interact at the opioid receptors that are primarily used acute and chronic pain relief. There are many different opioids that differ in their mode of action, duration of action, abuse potential, adverse effects, route of administration, and potency.


Opioids Narcotics Morphine 



Chronic non-cancerous pain


Chronic opioid therapy




Extended release


Gamma-aminobutyric acid


Immediate release


Medicines and Healthcare products Regulatory Agency


Rate corrected QT




  1. 1.
    Breasted JG. Ancient records of Egypt. University of Chicago Oriental Institute Publications. vol. III. Chicago: University of Chicago Press; 1930. p. 217.Google Scholar
  2. 2.
    Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008;11:S5–62 [opioids special issue].PubMedGoogle Scholar
  3. 3.
    Warner EA. Opioids for the treatment of noncancer pain. Am J Med. 2012;125(12):1155–61.CrossRefPubMedGoogle Scholar
  4. 4.
    Nestler EJ. Molecular basis on longterm plasticity underlying addiction. Nat Rev Neurosci. 2001;2:119–28.CrossRefPubMedGoogle Scholar
  5. 5.
    Fukuda K. Intravenous opioid anesthetics. In: Miller RD, editor. Miller’s anesthesia. 6th ed. Philadelphia: Elsevier; 2005.Google Scholar
  6. 6.
    Martell BA, O’Connor PG, Kerns RD, Becker WC, Morales KH, Kosten TR, Fiellin DA. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med. 2007;146(2):116–27.CrossRefPubMedGoogle Scholar
  7. 7.
    Noble M, Treadwell JR, Treager SJ, Coates VH, Wiffen PJ, Akafomo C, Schoelles KM. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010;1, CD006605.PubMedGoogle Scholar
  8. 8.
    Title 12, Chapter 13, Part B12: Schedules of controlled substances. DEA.
  9. 9.
    Chou R, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–30.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Manchikanti L, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 1—evidence assessment. Pain Physician. 2012;15:S1–66.PubMedGoogle Scholar
  11. 11.
    Manchikanti L, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2—guidance. Pain Physician. 2012;15:S66–116.Google Scholar
  12. 12.
    Ackerman SJ, Knight T, Schein J, et al. Risk of constipation in patients prescribed fentanyl transdermal system or oxycodone hydrochloride controlled-release in a California Medicaid population. Consult Pharm. 2004;19:118–32.CrossRefPubMedGoogle Scholar
  13. 13.
    Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R. Drug-induced urinary retention: incidence, management and prevention. Drug Saf. 2008;31(5):373–88.CrossRefPubMedGoogle Scholar
  14. 14.
    Ganesh A, Maxwell LG. Pathophysiology and management of opioid-induced pruritis. Drugs. 2007;67(16):2323–32.CrossRefPubMedGoogle Scholar
  15. 15.
    Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician. 2006;74(8):1347–54.PubMedGoogle Scholar
  16. 16.
    Lee M, Silverman S, Hansen H, Patel V, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14:145–61.PubMedGoogle Scholar
  17. 17.
    Kishner S. Opioid equivalents. eMedicine from WebMD, August 7; 2012.Google Scholar
  18. 18.
    Derby S, Chin J, Portenoy RK. Systemic opioid therapy for chronic cancer pain: practical guidelines for converting drugs and routes of administration. CNS Drugs. 1999;9(2):99–109.CrossRefGoogle Scholar
  19. 19.
    Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Gilman AG, Goodman LS, Rall TW, et al., editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: Macmillan Publishing Company; 1985. p. 491–531.Google Scholar
  20. 20.
    MHRA and Commission on Human Medicines. Risk of QT interval prolongation with methadone. Report no.: 31; 2006.Google Scholar
  21. 21.
    Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol. 1993;72:23B–5B.CrossRefPubMedGoogle Scholar
  22. 22.
    Katchman AN, McGroary KA, Kilborn MJ, et al. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. J Pharmacol Exp Ther. 2002;303:688–94.CrossRefPubMedGoogle Scholar
  23. 23.
    Mayet S, Gossop M, Lintzeris N, Markides V, Strang J. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation? Drug Alcohol Rev. 2011;30(4):388–96.CrossRefPubMedGoogle Scholar
  24. 24.
    Kahn LH, Alderfer RJ, Graham DJ. Seizures reported with Tramadol. JAMA. 1997;278:1661.CrossRefPubMedGoogle Scholar
  25. 25.
    Lewis JW. Buprenorphine. Drug Alcohol Depend. 1985;14:363–72.CrossRefPubMedGoogle Scholar
  26. 26.
    Tzschentke TM, Christoph T, Kögel B, Schiene K, Hennies HH, Englberger W, Haurand M, Jahnel U, Cremers TI, Friderichs E, De Vry J. Tapentadol HCl: a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007;323(1):265–76.CrossRefPubMedGoogle Scholar
  27. 27.
    Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112–20.CrossRefPubMedGoogle Scholar
  28. 28.
    Ferrel B, Argoff CE, Epplin J, Fine P, Gloth 3rd FM, Herr K, Katz JD, Mehr DR, Reid MC, Reisner L. American geriatrics society panel on the pharmacological management of persisting pain in older persons. Pain Med. 2009;10(6):1062–83.CrossRefGoogle Scholar
  29. 29.
    Brookoff D. Abuse potential of various opioid medications. J Gen Intern Med. 1993;8(12):688–90.CrossRefPubMedGoogle Scholar
  30. 30.
    Alford D, Compton P, Samet J. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med. 2006;144(2):127–34.PubMedCentralCrossRefPubMedGoogle Scholar
  31. 31.
    Kehlet H, Dahl JB. The value of “multimodal” or “balanced analgesia” in postoperative pain treatment. Anesth Analg. 1993;77:1048–56.CrossRefPubMedGoogle Scholar
  32. 32.
    Botney M, Fields HL. Amitriptyline potentiates morphine analgesia by a direct action on the central nervous system. Ann Neurol. 1983;13:160–4.CrossRefPubMedGoogle Scholar
  33. 33.
    Mitra S, Sinatra RS. Perioperative management of acute pain in the opioid-dependent patient. Anesthesiology. 2004;101:212–27.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of Physical Medicine and RehabilitationLouisiana State University School of Medicine, New OrleansNew OrleansUSA
  2. 2.Department of Family MedicineEast Jefferson General HospitalMetairieUSA

Personalised recommendations